Loading...

PE anti-mouse CD8a Antibody

Pricing & Availability
Clone
53-6.7 (See other available formats)
Regulatory Status
RUO
Other Names
T8, Lyt2, Ly-2
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
1_53-6dot7_PE_041106
C57BL/6 mouse splenocytes were stained with CD8 (clone 53-6.7) PE (filled histogram) or rat IgG2a, κ PE isotype control (open histogram).
  • 1_53-6dot7_PE_041106
    C57BL/6 mouse splenocytes were stained with CD8 (clone 53-6.7) PE (filled histogram) or rat IgG2a, κ PE isotype control (open histogram).
  • 2_53-67_PE_CD8a_Antibody_2_040122
    C57BL/6 mouse splenocytes were stained with CD8a (clone 53-6.7) PE (solid line) or rat IgG2a, κ PE isotype control (dashed line).
Compare all formats See PE spectral data
Cat # Size Price Quantity Check Availability Save
100707 50 µg 37 CHF
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100708 200 µg 107 CHF
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD8, also known as Lyt-2, Ly-2, or T8, consists of disulfide-linked α and β chains that form the α(CD8a)/β(CD8b) heterodimer and α/α homodimer. CD8a is a 34 kD protein that belongs to the immunoglobulin family. The CD8 α/β heterodimer is expressed on the surface of most thymocytes and a subset of mature TCR α/β T cells. CD8 expression on mature T cells is non-overlapping with CD4. The CD8 α/α homodimer is expressed on a subset of γ/δ TCR-bearing T cells, NK cells, intestinal intraepithelial lymphocytes, and lymphoid dendritic cells. CD8 is an antigen co-receptor on T cells that interacts with MHC class I on antigen-presenting cells or epithelial cells. CD8 promotes T cell activation through its association with the TCR complex and protein tyrosine kinase lck.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Mouse thymus or spleen
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The CD8a antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 106 cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

Clone 53-6.7 antibody competes with clone 5H10-1 antibody for binding to thymocytes3. The 53-6.7 antibody has been reported to block antigen presentation via MHC class I and inhibit T cell responses to IL-2. This antibody has also been used for depletion of CD8a+ cells. Additional reported applications (for the relevant formats) include: immunoprecipitation1,3, in vivo and in vitro cell depletion2,10,15, inhibition of CD8 T cell proliferation3, blocking of cytotoxicity3,4, immunohistochemical staining5,6 of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections, and spatial biology (IBEX)29,30. Clone 53-6.7 is not recommended for immunohistochemistry of formalin-fixed paraffin sections. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays or in vivo studies (Cat No. 100746).

Application References

(PubMed link indicates BioLegend citation)
  1. Ledbetter JA, et al. 1979. Immunol. Rev. 47:63. (IHC, IP)
  2. Hathcock KS. 1991. Current Protocols in Immunology. 3.4.1. (Deplete)
  3. Takahashi K, et al. 1992. P. Natl. Acad. Sci. USA 89:5557. (Block, IP)
  4. Ledbetter JA, et al. 1981. J. Exp. Med. 153:1503. (Block)
  5. Hata H, et al. 2004. J. Clin. Invest. 114:582. (IHC)
  6. Fan WY, et al. 2001. Exp. Biol. Med. 226:1045. (IHC)
  7. Shih FF, et al. 2006. J. Immunol. 176:3438. (FC)
  8. Kamimura D, et al. 2006. J. Immunol. 177:306.
  9. Bouwer HGA, et al. 2006. P. Natl. Acad. Sci. USA 103:5102. (FC, Deplete)
  10. Kao C, et al. 2005. Int. Immunol. 17:1607. PubMed
  11. Ko SY, et al. 2005. J. Immunol. 175:3309. (FC) PubMed
  12. Rasmussen JW, et al. 2006. Infect. Immun. 74:6590. PubMed
  13. Lee CH, et al. 2009. Clin. Cancer Res. PubMed
  14. Geiben-Lynn R, et al. 2008. Blood 112:4585. (Deplete) PubMed
  15. Kingeter LM, et al. 2008. J. Immunol. 181:6244. PubMed
  16. Guo Y, et al. 2008. Blood 112:480. PubMed
  17. Andrews DM, et al. 2008. J. Virol. 82:4931. PubMed
  18. Britschqui MR, et al. 2008. J. Immunol. 181:7681. PubMed
  19. Kenna TJ, et al. 2008. Blood 111:2091. PubMed
  20. Jordan JM, et al. 2008. Infect. Immun. 76:3717. PubMed
  21. Todd DJ, et al. 2009. J. Exp. Med. 206:2151. PubMed
  22. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  23. Medyouf H, et al. 2010. Blood 115:1175. PubMed
  24. Riedl P, et al. 2009. J. Immunol. 183:370. PubMed
  25. Apte SH, et al. 2010. J. Immunol. 185:998. PubMed
  26. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  27. del Rio ML, et al. 2011. Transpl. Int. 24:501. (FC) PubMed
  28. Cui L, et al. 2015. J Control Release. 206:220. PubMed
  29. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  30. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Li B, Schmidt N 2016. PLoS One. 11: 0162427. PubMed
  2. Sun L, et al. 2021. Cancer Cell. 39:1361. PubMed
  3. Xu C, et al. 2017. Biochemical and Biophysical Research Communications. 10.1016/j.bbrc.2017.05.071. PubMed
  4. Grigsby SM, et al. 2021. Cancers (Basel). 13:. PubMed
  5. Lawson H, et al. 2021. Stem Cell Reports. 16:2784. PubMed
  6. Li Z, et al. 2022. Nat Commun. 13:1845. PubMed
  7. Zelenka T, et al. 2022. Nat Commun. 13:6954. PubMed
  8. Chen X, et al. 2009. Hum Immunol. 70:79. PubMed
  9. Paris J et al. 2019. Cell Stem Cell. 25(1):137-148 . PubMed
  10. Iwamoto H et al. 2018. Cell metabolism. 28(1):104-117 . PubMed
  11. Schloss MJ, et al. 2022. Nat Immunol. 23:605. PubMed
  12. Wu SY, et al. 2022. Mol Cancer. 21:84. PubMed
  13. Lee S, et al. 2021. JCI Insight. 6:. PubMed
  14. Manukian G, et al. 2021. Int J Radiat Oncol Biol Phys. 110:1341. PubMed
  15. Aguilera T, et al. 2016. Nat Commun. 7:13898. PubMed
  16. Hu HJ, et al. 2020. Cell Death Dis. 1.168055556. PubMed
  17. Yu K, et al. 2021. Cell Reports. 35(12):109273. PubMed
  18. Kagoya Y, et al. 2018. Nat Commun. 9:1915. PubMed
  19. Misumi I et al. 2019. Cell Rep. 27(5):1387-1396 . PubMed
  20. Du Q, et al. 2019. Front Microbiol. 10:2050. PubMed
  21. Huang X, et al. 2019. Cancer Immunol Res. 1.388888889. PubMed
  22. Hsu SPC, et al. 2020. J Neurooncol. 146:417. PubMed
  23. Qin Y, et al. 2021. Cell Rep. 37:109968. PubMed
  24. Sng XYX, et al. 2020. J Immunol. 204:3108. PubMed
  25. Zhang S, et al. 2022. Cell Death Dis. 13:844. PubMed
  26. Plumlee CR, et al. 2020. Cell Host Microbe. 29(1):68-82.e5. PubMed
  27. Wong J, et al. 2015. Elife. 3: 07839. PubMed
  28. Ibrahim M, et al. 2016. J Evid Based Complementary Altern Med. 21: 171 - 176. PubMed
  29. He Y, et al. 2020. Sci Adv. 6:eaba7589. PubMed
  30. Zhao B, et al. 2020. Nat Commun. 11:908. PubMed
  31. van Erp EA, et al. 2019. Viruses. 0.811111111. PubMed
  32. Yuzhu Hou et al. 2018. Immunity. 49(3):490-503 . PubMed
  33. Diao L, et al. 2022. iScience. 25:105511. PubMed
  34. Ren J, et al. 2021. Theranostics. 11:304. PubMed
  35. Liu W, et al. 2021. Cell Mol Immunol. 18:2660. PubMed
  36. N'guessan P, et al. 2011. Antioxid Redox Signal. 15:1693. PubMed
  37. Wang Y, et al. 2016. Sci Rep. 6:31881. PubMed
  38. Felker A, Croy B 2016. J Leukoc Biol. 100: 645 - 655. PubMed
  39. Misumi I et al. 2019. Cell Rep. 27(2):514-524 . PubMed
  40. Jin X, et al. 2019. Mol Cell. 73:22:00. PubMed
  41. Tsuchiya N, et al. 2020. Cell Reports. 29(1):162-175.e9.. PubMed
  42. Demircioglu F, et al. 2020. Nat Commun. 11:1290. PubMed
  43. Chaurasiya S, et al. 2020. Oncoimmunology. 9:1729300. PubMed
  44. Glaubitz J, et al. 2022. Nat Commun. 13:4502. PubMed
  45. Papafragkos I, et al. 2022. Front Immunol. 13:889075. PubMed
  46. Tian X, et al. 2022. Front Immunol. 13:875236. PubMed
  47. Mitchell JE, et al. 2021. Cell Reports. 35(2):108966. PubMed
  48. Han C, et al. 2021. Cell Reports. 34(6):108706. PubMed
  49. Sharma S, et al. 2015. J Immunol. 194:5529. PubMed
  50. Shade K, et al. 2015. J Exp Med. 212:457. PubMed
  51. Lo W, Allen D 2012. Nat Immunol. 13:880. PubMed
  52. Peng L, et al. 2020. Transl Lung Cancer Res. 0.892361111. PubMed
  53. Rana A, et al. 2020. Front Immunol. 11:536. PubMed
  54. Morabito KM, et al. 2017. Mucosal Immunol. 0.795138889. PubMed
  55. Uchimura T et al. 2018. Immunity. 49(6):1049-1061 . PubMed
  56. Mauduit O, et al. 2022. Front Immunol. 13:1011125. PubMed
  57. Uchida A, et al. 2021. J Inflamm Res. 14:3089. PubMed
  58. Jia L, et al. 2022. Front Immunol. 13:897879. PubMed
  59. Li H, et al. 2021. Nat Commun. 12:2773. PubMed
  60. Zhang Z, et al. 2021. Oncoimmunology. 10:1912472. PubMed
  61. Zhang Y, et al. 2015. PLoS Pathog. 11: e1005167. PubMed
  62. Montel-Hagen A, et al. 2020. Cell Rep. 33:108320. PubMed
  63. Levine LS, et al. 2021. Immunity. 54(4):829-844.e5. PubMed
  64. Perry JSA, et al. 2018. Immunity. 48:923. PubMed
  65. Li J, et al. 2019. JCI Insight. 5. PubMed
  66. Meyer LK, et al. 2019. J Clin Invest. 130:863. PubMed
  67. Davidson S, et al. 2020. Cell Reports. 31(7):107628. PubMed
  68. Marchingo JM, et al. 2020. eLife. 9:e53725.. PubMed
  69. Wei JL, et al. 2021. J Immunother Cancer. 9: . PubMed
  70. Edwards CJ, et al. 2021. Br J Cancer. . PubMed
  71. Dang Y, et al. 2022. Cancer Cell Int. 22:88. PubMed
  72. Wang B, et al. 2022. Nat Commun. 13:3821. PubMed
  73. Ebina-Shibuya R, et al. 2021. Elife. 10:. PubMed
  74. Li H, et al. 2022. Theranostics. 12:6422. PubMed
  75. Burrack K, et al. 2015. PLoS Pathog. 11: e1005191. PubMed
  76. Frazier T, et al. 2018. Adipocyte. 0.41875. PubMed
  77. Naing A et al. 2019. Cell reports. 26(5):1242-1257 . PubMed
  78. Yang R, et al. 2022. Front Pharmacol. 13:774440. PubMed
  79. Hu G, et al. 2022. Cell Death Dis. 13:640. PubMed
  80. Spinner C, et al. 2015. Sci Rep. 5:16269. PubMed
  81. Qi T, et al. 2020. Cell Rep. 33:108452. PubMed
  82. Dietmar Herndler‐Brandstetter et al. 2018. Immunity. 48(4):716-729 . PubMed
  83. Zhang W, et al. 2019. Oncol Lett. 17:815. PubMed
  84. Lee CG, et al. 2019. JCI Insight. 4:5. PubMed
  85. Niemann J, et al. 2019. Nat Commun. 10:3236. PubMed
  86. Paul S, et al. 2018. Appl Microbiol Biotechnol. 102:8895. PubMed
  87. Hu Q, et al. 2018. Nat Biomed Eng. 0.660416667. PubMed
  88. Wang Y, et al. 2021. Front Immunol. 12:654463. PubMed
  89. Lu Y, et al. 2021. Gastroenterology. 161:575. PubMed
  90. Sá da Bandeira D, et al. 2022. Cell Rep. 40:111114. PubMed
  91. Zhong W, et al. 2022. Nat Commun. 13:4390. PubMed
  92. Yang H, et al. 2022. Nutrients. 14:. PubMed
  93. Glaros V, et al. 2021. Immunity. 54:2005. PubMed
  94. Sido J, et al. 2015. J Leukoc Biol. 98: 435-447. PubMed
  95. Burrack K, et al. 2015. J Immunol. 194:678. PubMed
  96. Parhi L, et al. 2020. Nat Commun. 2.721527778. PubMed
  97. Frodermann V, et al. 2019. Nat Med. 25:1761. PubMed
  98. Becher J, et al. 2018. Dev Cell. 47:592. PubMed
  99. van Montfoort N, et al. 2018. Cell. 175:1744. PubMed
  100. Habib S, et al. 2018. Infect Immun. 86:e00019. PubMed
  101. Pilones KA, et al. 2020. Cancer Immunol Res. 8:1054. PubMed
  102. James OJ, et al. 2021. Nat Commun. 12:4290. PubMed
  103. Zhao X, et al. 2013. Int Immunopharmacol. 17:793. PubMed
  104. Lu X, et al. 2015. J Immunol. 194:2011. PubMed
  105. Schuldt N, et al. 2015. PLoS One. 10: 0145762. PubMed
  106. Cai Y, et al. 2019. Cell Rep. 27:3034. PubMed
  107. Guo C, et al. 2017. Methods Mol Biol. 1709:345. PubMed
  108. Burr ML, et al. 2019. Cancer Cell. 36:385. PubMed
  109. Loh Z, et al. 2020. PLOS Pathogens. 16(7):e1008651. PubMed
  110. Liang J, et al. 2020. Sci Adv. 6:eabc3646. PubMed
  111. Cho K, et al. 2021. iScience. 24:103117. PubMed
  112. Sun C, et al. 2022. J Adv Res. 35:71. PubMed
  113. Monaghan KL, et al. 2020. J Vis Exp. . PubMed
  114. Chou T, et al. 2016. Nat Commun. 7:11904. PubMed
  115. Thomas AM, et al. 2020. Journal of Cellular Physiology. 235(6):5120-5129.. PubMed
  116. Manrique-Rincón A, et al. 2017. Front Immunol. 10.3389/fimmu.2017.01150. PubMed
  117. Chan WF, et al. 2022. Nat Commun. 13:5582. PubMed
  118. Moutuou MM, et al. 2020. Methods Mol Biol. 2111:267. PubMed
  119. Frost JN, et al. 2021. Med (N Y). 2:164. PubMed
  120. Anderson AE, et al. 2022. NPJ Regen Med. 7:6. PubMed
  121. Lin J, et al. 2021. Nat Commun. 12:5321. PubMed
  122. Bates PD, et al. 2021. Front Immunol. 12:668307. PubMed
  123. Kmieciak M, et al. 2011. J Vis Exp. 47: 2381. PubMed
  124. Wei Z, et al. 2021. Nat Commun. 0.805555556. PubMed
  125. Melo-Silva CR, et al. 2021. PLOS Pathogens. 17(5):e1009593. PubMed
  126. Echevarría-Vargas IM, et al. 2018. EMBO Mol Med. 10:e8446. PubMed
  127. Subramanian K, et al. 2019. Nat Microbiol. 4:62. PubMed
  128. Watson MJ, et al. 2021. Nature. 591:645. PubMed
  129. Wu S, et al. 2021. Nat Cancer. 2:189. PubMed
  130. Chen C, et al. 2021. J Virol. 95:e0082921. PubMed
  131. Schreiber K, et al. 2020. Cancer Immunol Res. 8:192. PubMed
  132. Han Y, et al. 2022. Int J Biol Sci. 18:5653. PubMed
  133. Gomez S, et al. 2022. J Immunother Cancer. 10:. PubMed
  134. Liu Y, et al. 2020. Oncol Lett. 2369:20. PubMed
  135. Li J, et al. 2020. FASEB J. 34:3091. PubMed
  136. Cai Z, et al. 2020. Cell Rep. 31:107816. PubMed
  137. Rodriguez-Sosa M, et al. 2004. Infect Immun. 72:4552. PubMed
  138. Kamata T, et al. 2020. Cell Reports. 31(12):107802. PubMed
  139. Wong YC, et al. 2019. J Virol. 93:e01154-19. PubMed
  140. Yuan X, et al. 2017. Elife. 6:e29540. PubMed
  141. Zhang J, et al. 2018. Nature. 553:91. PubMed
  142. Li Z, et al. 2022. Nat Commun. 13:6321. PubMed
  143. Kim DK, et al. 2022. Nat Commun. 13:6292. PubMed
  144. Dong M, et al. 2022. J Immunother Cancer. 10:. PubMed
  145. Shen DD, et al. 2022. Mol Cancer. 21:75. PubMed
  146. Zhu J, et al. 2021. Cancer Cell Int. 21:529. PubMed
  147. Baranwal G, et al. 2021. Physiol Rep. 9:e15094. PubMed
  148. Bristow CL, et al. 2021. Front Oncol. 11:739080. PubMed
  149. Li J, et al. 2020. Development. :. PubMed
  150. Pai M, et al. 2016. JPEN J Parenter Enteral Nutr. 40: 383 - 391. PubMed
  151. Kovacs SB, et al. 2021. STAR Protoc. 2:100244. PubMed
  152. Onai N, et al. 2020. Int J Mol Sci. :22. PubMed
  153. Xia Y, et al. 2018. Cell. 175:1059. PubMed
  154. Eisemann T, et al. 2019. Front Oncol. 9:187. PubMed
  155. Chen X, et al. 2019. Med Sci Monit. 25:5389. PubMed
  156. Oliveira AC et al. 2017. eLife. 6 pii: e30883. PubMed
  157. Cartwright ANR, et al. 2021. Cancer Immunol Res. 9:470. PubMed
  158. Tsai SJ, et al. 2021. J Biol Chem. 297:101266. PubMed
  159. Ene CI, et al. 2020. Neuro Oncol. 639:22. PubMed
  160. Si J, et al. 2020. Cancer Cell. 38(4):551-566.e11. PubMed
  161. Xu C, et al. 2020. Immunity. 53(2):417-428.e4. PubMed
  162. Flesch I, et al. 2015. J Immunol. 195: 2263-2272. PubMed
  163. Clemente–Casares X, et al. 2017. Immunity. 47:974. PubMed
  164. Liu Y, et al. 2018. Cancer Cell. 33:480. PubMed
  165. Koide S, et al. 2022. iScience. 25:103603. PubMed
  166. Kline JM, et al. 2021. J Biol Chem. :100373. PubMed
  167. Yang Z, et al. 2021. Nat Commun. 12:4299. PubMed
  168. Wong L, et al. 2013. J Biol Chem. 288:35170. PubMed
  169. Zhu E, et al. 2014. J Immunol. 192:5599. PubMed
  170. Wu Y, et al. 2015. J Immunol. 195: 2612-2623. PubMed
  171. Jia H, et al. 2018. Int J Oncol. 53:949. PubMed
  172. Kong XF, et al. 2018. Nat Immunol. 19:973. PubMed
  173. Yoshida H, et al. 2019. Cell. 176:897. PubMed
  174. Rodríguez L, et al. 2021. Biomolecules. 11: . PubMed
  175. Sugita Y, et al. 2021. Oncol Rep. 45:. PubMed
  176. Sun F, et al. 2022. Cell Death Dis. 13:181. PubMed
  177. Wu G, et al. 2021. Nat Cancer. 2:1170. PubMed
  178. Yang N, et al. 2022. Nat Commun. 13:2336. PubMed
  179. Schnoegl D, et al. 2022. Front Immunol. 13:909270. PubMed
  180. Fedele C, et al. 2021. J Exp Med. 218: . PubMed
  181. Bonavita E, et al. 2020. Immunity. 1215:53. PubMed
  182. Aguilera TA, et al. 2020. Clin Cancer Res. 26:2972. PubMed
  183. LeBlanc P, et al. 2014. J Biol Chem. 289:7777. PubMed
  184. Yamashita M, et al. 2019. Cell Stem Cell. 25:357. PubMed
  185. Lu Y, et al. 2018. Cancer Cell. 33:1048. PubMed
  186. Skirecki T, et al. 2020. JCI Insight. 5:. PubMed
  187. Sun Y, et al. 2022. iScience. 25:104846. PubMed
  188. Barsoumian HB, et al. 2022. Cancers (Basel). 14:. PubMed
  189. Lin J, et al. 2021. Cancer Immunol Res. 9:1413. PubMed
  190. Chavez JS, et al. 2022. Cells. 11:. PubMed
  191. Wang X, et al. 2022. Elife. 11:. PubMed
  192. Wang F, et al. 2021. Neoplasia. 23:281. PubMed
  193. Wang X, et al. 2021. Theranostics. 11:209. PubMed
  194. Angela M, et al. 2016. Nat Commun. 7:13683. PubMed
  195. Kang YA, et al. 2020. J Exp Med. 217:00:00. PubMed
  196. Tran S, et al. 2020. Immunity. 53(3):627-640.e5. PubMed
  197. Heyde A, et al. 2021. Cell. 184(5):1348-1361.e22. PubMed
  198. Ren D, et al. 2020. Am J Cancer Res. 2851:10. PubMed
  199. Zeng A, et al. 2020. Oncol Rep. . PubMed
  200. Radulovic V, et al. 2020. Cell Reports. 27(10):2826-2836.e5.. PubMed
  201. Chen R, et al. 2021. Front Oncol. 11:743050. PubMed
  202. Dourcy M, et al. 2020. Mucosal Immunol. 13:799. PubMed
  203. Zhang M, et al. 2022. iScience. 25:104490. PubMed
  204. Gawish R, et al. 2022. Elife. 11:. PubMed
  205. Lv K, et al. 2021. Cell Stem Cell. 28(7):1275-1290.e9. PubMed
  206. Yang E, et al. 2015. Acta Biochim Biophys Sin. 47: 588-596. PubMed
  207. Zhou T, et al. 2018. Mol Med Rep. 17:4883. PubMed
  208. Lee YT, et al. 2018. PLoS One. 13:e0190868. PubMed
  209. Quijano-Rubio A, et al. 2022. Nat Biotechnol. Online ahead of print. PubMed
  210. Xu Z, et al. 2022. Cell Death Dis. 13:502. PubMed
  211. Pastor Arroyo EM, et al. 2022. Clin Sci (Lond). 136:557. PubMed
  212. Shi GN, et al. 2021. Ther Adv Med Oncol. 13:1758835920987056. PubMed
RRID
AB_312746 (BioLegend Cat. No. 100707)
AB_312747 (BioLegend Cat. No. 100708)

Antigen Details

Structure
Ig superfamily, CD8α chain, 34 kD
Distribution

Most thymocytes, T cell subset, some NK cells, lymphoid dendritic cells

Function
Co-receptor for TCR
Ligand/Receptor
MHC class I molecule
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Zamoyska R. 1994. Immunity 1:243.
3. Ellmeier W, et al. 1999. Annu. Rev. Immunol. 17:523.

Gene ID
12525 View all products for this Gene ID
UniProt
View information about CD8alpha on UniProt.org

Related FAQs

What type of PE do you use in your conjugates?
We use R-PE in our conjugates.

Other Formats

View All CD8a Reagents Request Custom Conjugation
Description Clone Applications
APC anti-mouse CD8a 53-6.7 FC
Biotin anti-mouse CD8a 53-6.7 FC,IHC
FITC anti-mouse CD8a 53-6.7 FC
PE anti-mouse CD8a 53-6.7 FC
PE/Cyanine5 anti-mouse CD8a 53-6.7 FC
Purified anti-mouse CD8a 53-6.7 FC,CyTOF®,IHC-F,IP
PE/Cyanine7 anti-mouse CD8a 53-6.7 FC
APC/Cyanine7 anti-mouse CD8a 53-6.7 FC
Alexa Fluor® 488 anti-mouse CD8a 53-6.7 FC,3D IHC
Alexa Fluor® 647 anti-mouse CD8a 53-6.7 FC,IHC-F,3D IHC,SB
Pacific Blue™ anti-mouse CD8a 53-6.7 FC
Alexa Fluor® 700 anti-mouse CD8a 53-6.7 FC
PerCP/Cyanine5.5 anti-mouse CD8a 53-6.7 FC
PerCP anti-mouse CD8a 53-6.7 FC
Brilliant Violet 421™ anti-mouse CD8a 53-6.7 FC,IHC,SB
Brilliant Violet 570™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 650™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 605™ anti-mouse CD8a 53-6.7 FC
Ultra-LEAF™ Purified anti-mouse CD8a 53-6.7 FC,CyTOF®,IHC,IP,Depletion,Block
Brilliant Violet 711™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 785™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 510™ anti-mouse CD8a 53-6.7 FC
Purified anti-mouse CD8a (Maxpar® Ready) 53-6.7 FC,CyTOF®
Alexa Fluor® 594 anti-mouse CD8a 53-6.7 IHC-F,FC,3D IHC
PE/Dazzle™ 594 anti-mouse CD8a 53-6.7 FC
APC/Fire™ 750 anti-mouse CD8a 53-6.7 FC
GoInVivo™ Purified anti-mouse CD8a 53-6.7 FC
TotalSeq™-A0002 anti-mouse CD8a 53-6.7 PG
Spark Blue™ 550 anti-mouse CD8a 53-6.7 FC
Spark NIR™ 685 anti-mouse CD8a 53-6.7 FC
TotalSeq™-C0002 anti-mouse CD8a 53-6.7 PG
TotalSeq™-B0002 anti-mouse CD8a 53-6.7 PG
Spark YG™ 570 anti-mouse CD8a 53-6.7 IHC-F
PE/Fire™ 640 anti-mouse CD8a 53-6.7 FC
PE/Fire™ 700 anti-mouse CD8a 53-6.7 FC
Spark Blue™ 574 anti-mouse CD8a Antibody 53-6.7 FC
Spark Violet™ 423 anti-mouse CD8a Antibody 53-6.7 FC
Spark UV™ 387 anti-mouse CD8a 53-6.7 FC
Spark Blue™ 515 anti-mouse CD8a 53-6.7 FC
APC/Fire™ 810 anti-mouse CD8a 53-6.7 FC
Spark Red™ 718 anti-mouse CD8a (Flexi-Fluor™) 53-6.7 FC
PE/Fire™ 810 anti-mouse CD8a 53-6.7 FC
Spark PLUS UV™ 395 anti-mouse CD8a 53-6.7 FC
Go To Top Version: 2    Revision Date: 01.21.2014

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account